Concurrent implantation of sirolimus- and paclitaxel-eluting stents in the same vessel

Simon J. Corbett, John Cosgrave, Antonio Colombo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To assess the safety and efficacy of concurrent implantation of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents in the same coronary artery. Background: When it is impossible to deliver multiple drug eluting stents (DES) of the same type, the operator must opt to implant a different DES or a bare metal stent. There are currently no published data evaluating this approach. Methods: We identified all cases in which one or more SES and PES were implanted in either the same lesion or adjacent segments of the same vessel during a single procedure between March 2003 and March 2005. Endpoints analyzed were; in-hospital major adverse cardiac events (MACE), and follow-up MACE (including stent thrombosis). Results: We identified 44 patients with 89 lesions. This was a complex cohort of patients with a median of 3.5 stents implanted, 3 lesions and 2 vessels treated and a median stent length implanted of 80.5 mm, while 83% of the lesions were type B2/C. Eight patients had peri-procedural myocardial infarction. During follow-up; 1 cardiac death occurred, no patients had a myocardial infarct or stent thrombosis, 11 underwent target lesion and vessel revascularization (25%) and 13 had a major adverse cardiac event (29.5%). Conclusions: In this cohort of patients, the concurrent use of SES and PES in the same vessel was associated with outcomes in keeping with the complexity of disease treated. Our data show that it is not unreasonable to implant different DES in the same vessel, although we would not advocate this as routine practice.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume69
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Sirolimus
Paclitaxel
Stents
Drug-Eluting Stents
Thrombosis
Myocardial Infarction
Coronary Vessels
Metals
Safety

Keywords

  • Paclitaxel
  • Sirolimus
  • Stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Concurrent implantation of sirolimus- and paclitaxel-eluting stents in the same vessel. / Corbett, Simon J.; Cosgrave, John; Colombo, Antonio.

In: Catheterization and Cardiovascular Interventions, Vol. 69, No. 1, 01.2007, p. 109-114.

Research output: Contribution to journalArticle

Corbett, Simon J. ; Cosgrave, John ; Colombo, Antonio. / Concurrent implantation of sirolimus- and paclitaxel-eluting stents in the same vessel. In: Catheterization and Cardiovascular Interventions. 2007 ; Vol. 69, No. 1. pp. 109-114.
@article{2d4897732f60464ea6ede075650bee3d,
title = "Concurrent implantation of sirolimus- and paclitaxel-eluting stents in the same vessel",
abstract = "Objective: To assess the safety and efficacy of concurrent implantation of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents in the same coronary artery. Background: When it is impossible to deliver multiple drug eluting stents (DES) of the same type, the operator must opt to implant a different DES or a bare metal stent. There are currently no published data evaluating this approach. Methods: We identified all cases in which one or more SES and PES were implanted in either the same lesion or adjacent segments of the same vessel during a single procedure between March 2003 and March 2005. Endpoints analyzed were; in-hospital major adverse cardiac events (MACE), and follow-up MACE (including stent thrombosis). Results: We identified 44 patients with 89 lesions. This was a complex cohort of patients with a median of 3.5 stents implanted, 3 lesions and 2 vessels treated and a median stent length implanted of 80.5 mm, while 83{\%} of the lesions were type B2/C. Eight patients had peri-procedural myocardial infarction. During follow-up; 1 cardiac death occurred, no patients had a myocardial infarct or stent thrombosis, 11 underwent target lesion and vessel revascularization (25{\%}) and 13 had a major adverse cardiac event (29.5{\%}). Conclusions: In this cohort of patients, the concurrent use of SES and PES in the same vessel was associated with outcomes in keeping with the complexity of disease treated. Our data show that it is not unreasonable to implant different DES in the same vessel, although we would not advocate this as routine practice.",
keywords = "Paclitaxel, Sirolimus, Stent",
author = "Corbett, {Simon J.} and John Cosgrave and Antonio Colombo",
year = "2007",
month = "1",
doi = "10.1002/ccd.20913",
language = "English",
volume = "69",
pages = "109--114",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Concurrent implantation of sirolimus- and paclitaxel-eluting stents in the same vessel

AU - Corbett, Simon J.

AU - Cosgrave, John

AU - Colombo, Antonio

PY - 2007/1

Y1 - 2007/1

N2 - Objective: To assess the safety and efficacy of concurrent implantation of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents in the same coronary artery. Background: When it is impossible to deliver multiple drug eluting stents (DES) of the same type, the operator must opt to implant a different DES or a bare metal stent. There are currently no published data evaluating this approach. Methods: We identified all cases in which one or more SES and PES were implanted in either the same lesion or adjacent segments of the same vessel during a single procedure between March 2003 and March 2005. Endpoints analyzed were; in-hospital major adverse cardiac events (MACE), and follow-up MACE (including stent thrombosis). Results: We identified 44 patients with 89 lesions. This was a complex cohort of patients with a median of 3.5 stents implanted, 3 lesions and 2 vessels treated and a median stent length implanted of 80.5 mm, while 83% of the lesions were type B2/C. Eight patients had peri-procedural myocardial infarction. During follow-up; 1 cardiac death occurred, no patients had a myocardial infarct or stent thrombosis, 11 underwent target lesion and vessel revascularization (25%) and 13 had a major adverse cardiac event (29.5%). Conclusions: In this cohort of patients, the concurrent use of SES and PES in the same vessel was associated with outcomes in keeping with the complexity of disease treated. Our data show that it is not unreasonable to implant different DES in the same vessel, although we would not advocate this as routine practice.

AB - Objective: To assess the safety and efficacy of concurrent implantation of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents in the same coronary artery. Background: When it is impossible to deliver multiple drug eluting stents (DES) of the same type, the operator must opt to implant a different DES or a bare metal stent. There are currently no published data evaluating this approach. Methods: We identified all cases in which one or more SES and PES were implanted in either the same lesion or adjacent segments of the same vessel during a single procedure between March 2003 and March 2005. Endpoints analyzed were; in-hospital major adverse cardiac events (MACE), and follow-up MACE (including stent thrombosis). Results: We identified 44 patients with 89 lesions. This was a complex cohort of patients with a median of 3.5 stents implanted, 3 lesions and 2 vessels treated and a median stent length implanted of 80.5 mm, while 83% of the lesions were type B2/C. Eight patients had peri-procedural myocardial infarction. During follow-up; 1 cardiac death occurred, no patients had a myocardial infarct or stent thrombosis, 11 underwent target lesion and vessel revascularization (25%) and 13 had a major adverse cardiac event (29.5%). Conclusions: In this cohort of patients, the concurrent use of SES and PES in the same vessel was associated with outcomes in keeping with the complexity of disease treated. Our data show that it is not unreasonable to implant different DES in the same vessel, although we would not advocate this as routine practice.

KW - Paclitaxel

KW - Sirolimus

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=33845986707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845986707&partnerID=8YFLogxK

U2 - 10.1002/ccd.20913

DO - 10.1002/ccd.20913

M3 - Article

C2 - 17139626

AN - SCOPUS:33845986707

VL - 69

SP - 109

EP - 114

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -